Two research groups demonstrated the de novo assembly of a human genome and a tomato genome, using data from Oxford Nanopore's MinIon.
Pacific Biosciences reported total Q1 2017 revenues of $24.9 million, just beating analysts' average estimate of $24.6 million.
The two studies came out of the UK's Tracking Cancer Evolution through Therapy (TRACERx) trial.
Illumina's NovaSeq accessory, which it plans to launch in Q4, will enable customers to run different experiments and library types in different flow cell lanes.
The company said that it received orders for 135 of its NovaSeq sequencing instrument in the first quarter 2017.
The company plans to outlicense the assay, developed using a custom Affymetrix microarray, to an interested partner.
The survey, conducted by Bank of America Merrill Lynch and GenomeWeb, found that almost half of current NGS users plan to add new systems over the coming year.
The company hopes to accrue around 5,000 patients over the next few years, creating a broad dataset coupling outcomes with comprehensive DNA, RNA, and protein analyses.
Contrary to Illumina's reports that index switching is rare, the Stanford team found the issue occurred in more than 5 percent of sequence reads.
Grail plans to enroll up to 120,000 women who have been screened via mammogram, to train and validate its NGS-based early detection cancer test.
A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.
Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.
Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.
In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.